OR WAIT null SECS
June 26, 2022
Breyanzi is now available as a second-line treatment for this aggressive blood cancer.
June 23, 2022
Elacestrant is oral therapy that targets estrogen receptor 1, a key resistance mechanism in advanced breast cancer.
The FDA approved the combination of Tafinlar and Mekinist for solid tumors with a BRAF V600E mutation. This is the first therapy to be approved that is tumor agnostic for patients with this mutation.
June 20, 2022
A study in the journal Blood has found that the cost-effectiveness of the Polivy treatment regimen used to treat patients with diffuse large B-cell lymphoma would decrease if the five-year progression-free survival decreased.
Trial results showed overall survival was shorter compared with chemotherapy. The move doesn’t affect other indications.
June 19, 2022
Sierra Oncology is seeking approval of momelotinib as a treatment for patients with myelofibrosis, a bone marrow cancer.
June 15, 2022
But investigators found that U.S. approvals often come before publication of results.
June 13, 2022
The FDA needs time to review additional clinical data submitted by BeiGene for the leukemia/lymphoma indication. The new date is Jan. 20, 2023.
The FDA has set a PDUFA date of Jan. 29, 2023, but Merck indicated additional data may be provided to regulators that extends this date.
June 06, 2022
The FDA approved Orgovyx in December 2021 to treat patients with advanced prostate cancer.
